Additionally, in cases of bimodal CD49d CLL treated with multiple lines of therapy, we observed an increase in the sub-population of CD49pos cells, suggesting that CD49d expression plays a pivotal role in chemorefractoriness and disease potentiation. The gene discussed is ITGA4; the disease is B-cell chronic lymphocytic leukemia.